Further, Lgals3 ablation enhances liver steatosis, but attenuates inflammation and IL-33 dependant fibrosis in mouse model of non-alcoholic fatty liver disease (NAFLD) (Jeftic et al., 2015), and enhances bile duct damage and liver fibrosis in xenobiotic induced primary biliary cholangitis (PBC) (Arsenijevic et al., 2016). The gene discussed is IL33; the disease is metabolic dysfunction-associated steatotic liver disease.